S Novello

Summary

Country: Italy

Publications

  1. ncbi request reprint Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
    S Novello
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
    Ann Oncol 16:1662-6. 2005
  2. ncbi request reprint Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
  3. ncbi request reprint ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    P Ceppi
    Thoracic Oncology Unit, Orbassano, Torino, Italy
    Ann Oncol 17:1818-25. 2006
  4. ncbi request reprint Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    S Bovio
    Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
    J Endocrinol Invest 29:298-302. 2006
  5. ncbi request reprint Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
  6. ncbi request reprint Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Lung Cancer 34:261-9. 2001
  7. ncbi request reprint Pilot study of early repeated 18F-FDG PET during cycle 1 to predict objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)
    U Ricardi
    University of Turin, Turin, Italy University of Turin, Orbassano, Italy Nuclear Medicine, Turin, Italy
    J Clin Oncol 26:8003. 2008
  8. ncbi request reprint Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
  9. doi request reprint Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
    S Vatrano
    Division of Pathology, Department of Oncology, University of Turin at San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano Turin, Italy
    Target Oncol 11:157-66. 2016
  10. ncbi request reprint Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
    S Novello
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
    Ann Oncol 16:1662-6. 2005
    ..However, there is a considerable discrepancy among studies in the percentage of lung nodules, overall lung cancer and stage I detection rate...
  2. ncbi request reprint Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
    ....
  3. ncbi request reprint ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    P Ceppi
    Thoracic Oncology Unit, Orbassano, Torino, Italy
    Ann Oncol 17:1818-25. 2006
    ....
  4. ncbi request reprint Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    S Bovio
    Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
    J Endocrinol Invest 29:298-302. 2006
    ..Notwithstanding that our subjects were at increased risk of lung cancer, the rate of adrenal metastases was low. We think that the present results can be generalized even if we may disclose the lack of histological diagnosis...
  5. ncbi request reprint Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
    ....
  6. ncbi request reprint Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Lung Cancer 34:261-9. 2001
    ..CONCLUSION: In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated...
  7. ncbi request reprint Pilot study of early repeated 18F-FDG PET during cycle 1 to predict objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)
    U Ricardi
    University of Turin, Turin, Italy University of Turin, Orbassano, Italy Nuclear Medicine, Turin, Italy
    J Clin Oncol 26:8003. 2008
    ..Aim of this pilot study in patients (pts) with advanced NSCLC was to test if a second 18F-FDG PET repeated two weeks after the start of chemotherapy is predictive of subsequent response and survival...
  8. ncbi request reprint Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
    ..In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood...
  9. doi request reprint Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
    S Vatrano
    Division of Pathology, Department of Oncology, University of Turin at San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano Turin, Italy
    Target Oncol 11:157-66. 2016
    ..Resampling may provide tissue for additional tests to detect acquired resistance and/or new genetic alterations, but the currently available information is limited...
  10. ncbi request reprint Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005
    ..Based on resource consumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the treatment of advanced NSCLC in Italy...
  11. pmc Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
    Br J Cancer 101:1543-8. 2009
    ..Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC)...
  12. ncbi request reprint Current status of adjuvant chemotherapy in NSCLC
    G V Scagliotti
    Department of Clinical and Biological Sciences, S Luigi Hospital, Thoracic Oncology Unit, University of Turin, Torino, Italy
    Ann Oncol 17:v62-3. 2006
  13. ncbi request reprint State of the art in mesothelioma
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Orbassano Torino, Italy
    Ann Oncol 16:ii240-5. 2005
  14. ncbi request reprint Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
    G Selvaggi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Ann Oncol 15:28-32. 2004
    ..We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival...
  15. doi request reprint Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence
    S Novello
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, AOU San Luigi Orbassano, Italy
    Crit Rev Oncol Hematol 83:208-15. 2012
    ..This article discusses the assessment of treatment response in NSCLC patients using functional imaging, and emphasizes advantages and limitations in clinical management...
  16. ncbi request reprint Role of erythropoietin in the treatment of lung cancer associated anaemia
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Azienda Ospedaliera S Luigi, 10043 Orbassano, Torino, Italy
    Lung Cancer 34:S91-4. 2001
    ..This 'functional' level would be in keeping with the body's physiological erythropoietin response...
  17. ncbi request reprint Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly population
    C Mantovani
    Department of Medical and Surgical Sciences, Radiotherapy Unit, University of Turin, Italy
    Ann Oncol 17:ii61-63. 2006
  18. ncbi request reprint International tailored chemotherapy adjuvant trial: ITACA trial
    S Novello
    University of Turin, Orbassano, Italy Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Turin, Italy Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Department of Clinical and Biological Sciences University of Turin, Orbassano, Italy Pneumologia Evangelische Lungenklinik, Berlin, Germany Eugenio Morelli Hospital AOVV, Sondalo, Italy Regina Elena National Cancer Institute, Rome, Italy Medical Oncology Azienda Ospedaliera Santa Croce e Carle, Confreria Cuneo, Italy Lungenklinik Hemer, Hemer, Germany Lung Clinic, Hospital of the City of Cologne, Merheim, University Hospital Witten Herdecke, Cologne, Germany Klinikum Esslingen, Esslingen, Germany Medical Oncology AUO Giovanni Battista, Turin, Ivory Coast GIVOP Azienda Ospedaliero Universitaria Di Verona, Verona, Italy Universita degli Studi del Piemonte Orientale, Novara, Italy Klinik für Innere Medizin II, Uniklinikum Ulm, Ulm, Germany University Medical Center, Department of Physics
    J Clin Oncol 29:e17514. 2011
    ..In all registered patients, before randomization, expression of ERCC1 and TS is assessed by qRT-PCR on paraffin-embedded tumor specimens in a central laboratory...
  19. ncbi request reprint Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC)
    M G Vigano'
    Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy University of Turin, Orbassano, Italy Lung Cancer Unit, National Institute for Cancer Research, Genova, Italy Humanitas Cancer Center, Rozzano, Italy Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Turin, Italy Thoracic Oncology Unit, AUO San Luigi, Orbassano, University of Turin, Orbassano, Italy MolMed SpA, Milan, Italy
    J Clin Oncol 29:7077. 2011
    ..A phase I trial previously selected NGR-hTNF 0.8 µg/m2 + doxorubicin (D) 75 mg/m2 for further testing...
  20. doi request reprint Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
    G V Scagliotti
    Department of Oncology, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 26:497-504. 2015
    ..This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (NSCLC)...
  21. ncbi request reprint A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy
    F Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 52:319-25. 2006
    ..This study has been designed in order to explore two different approaches of gemcitabine dose intensification in patients with advanced NSCLC...
  22. ncbi request reprint European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer
    S Novello
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Semin Oncol 28:3-9. 2001
    ..The use of paclitaxel in regimens without platinum and in triplet combinations is also being studied, and the optimal manner in which to administer this active agent clearly is of interest...
  23. ncbi request reprint Is there a standard strategy in the management of locally advanced non-small cell lung cancer?
    S Novello
    Departement of Medicine, Institut Gustave Roussy, Villejuif, France
    Lung Cancer 34:S9-14. 2001
    ..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity...
  24. ncbi request reprint Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
    S Novello
    Department of Medicine, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Cancer 38:292-9. 2002
    ..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity...
  25. ncbi request reprint Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma
    S Faivre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1479-89. 2002
    ....
  26. ncbi request reprint Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
    C Monnerat
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:316-23. 2004
    ..This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin-gemcitabine...
  27. doi request reprint A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
    M H Cullen
    Cancer Centre, Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham, UK
    Ann Oncol 19:939-45. 2008
    ..This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy...
  28. pmc Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    F Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Via Altura 3, 40139 Bologna, Italy
    Br J Cancer 93:29-34. 2005
    ..Our results show that gemcitabine-oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving further study, especially for patients not eligible to receive cisplatin...
  29. ncbi request reprint Cytotoxic chemotherapy in advanced non-small cell lung cancer
    G V Scagliotti
    Monaldi Arch Chest Dis 63:181-3. 2005
  30. ncbi request reprint Women and lung cancer
    S Novello
    SSD Oncologia Polmonare Ospedale San Luigi Gonzaga Università di Torino, Turin
    Ann Oncol 17:ii79-82. 2006
  31. ncbi request reprint Treatment of advanced non-small cell lung cancer
    L De Petris
    5th Pneumo Oncology Unit, Deparment of Lung Diseases, S Camillo Forlanini Hospitals, Rome, Italy
    Ann Oncol 17:ii36-41. 2006
    ..With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients...